Drugs / COVAC-1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05693272 | Jan 2023 → Jun 2024 | COVID-19 | University of Saskatchewan | Completed | No outcome recorded |
| Phase 1 | NCT05155982 | Jun 2022 → Jun 2023 | COVID-19 | University of Saskatchewan | Withdrawn | No outcome recorded |
| Phase 1 | NCT04546841 | Nov 2020 → Sep 2021 | — | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04954469 | Jun 2021 → Aug 2022 | immunodeficiency disease | University Hospital Tuebingen | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoVac-1 | “A single vaccination with the IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides, XS15 emulsified in Montanide ISA 51 VG) (500 µl) will be applied subcutaneously (s.c.) to the abdominal skin.” NCT04546841 ↗4“CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response.” PMID 37596280 ↗ Aug 2023 |
| Action | Activate | “CoVac-1 is a peptide-based T-cell activator” PMID 37596280 ↗ Aug 2023 |
| Modality | Vaccine | “SARS-CoV-2 peptide vaccine” NCT04546841 ↗ |
| Route | Subcutaneous | “applied subcutaneously (s.c.)” NCT04546841 ↗ |